Quick answer
Radiotherapy treats prostate cancer with radiation, without any cut, and is given with curative intent in localized tumors.1 The most common form is external radiotherapy guided by imaging, in 5 to 39 sessions depending on the schedule.1,4,5 For intermediate and high risk, it is usually combined with hormone therapy, for 4 to 6 months or for 2 to 3 years.1 After surgery, it is an option when PSA starts rising again.1
Types of radiotherapy
In external radiotherapy, a machine rotates around the body and sends beams from several angles that add up in the prostate. The European guideline considers intensity-modulated radiotherapy (IMRT or VMAT) the standard, with images taken at each session to check the position of the prostate (IGRT).1 What changes between schedules is the dose per session and, with it, the number of sessions:
| Schedule | Sessions | For whom, according to the European guideline |
|---|---|---|
| Traditional | about 39, over 7.5 weeks5 | Intermediate and high risk1 |
| Moderate hypofractionation | 20 over 4 weeks or 28 over 6 weeks | Intermediate and high risk, as an alternative to the traditional schedule1 |
| Stereotactic (SBRT) | 5 sessions, or 7 on alternate days | Favorable intermediate risk, taking urinary function into account1 |
Fewer sessions did not mean less cancer control. In the CHHiP trial of 3,216 men, 20 sessions controlled the cancer as well as 37: at 5 years, 90.6% were free of failure, versus 88.3%.4 In PACE-B, stereotactic radiotherapy in 5 sessions had 95.8% free of failure at 5 years, versus 94.6% with longer schedules, with more urinary side effects.5 The European guideline advises avoiding stereotactic radiotherapy in men who already have severe urinary symptoms or a blockage to urine flow.1
In brachytherapy, small radiation sources are placed inside the prostate. On its own, low-dose-rate brachytherapy is indicated for favorable intermediate risk in men who urinate well, which the guideline defines with a symptom questionnaire (IPSS below 12) and a strong stream on a flow test.1 It can also be added to external radiotherapy as a dose boost in higher-risk cases.1
For low risk, the European guideline recommends active surveillance and considers radiotherapy, like surgery, more treatment than needed outside clinical trials.1 More in active surveillance.
What the sessions are like
Radiotherapy is planned and delivered by a radiation oncologist, the doctor who specializes in this treatment. Sessions are usually once a day, Monday to Friday.2
- Length. The radiation is delivered for a few minutes. Most of the visit, 30 minutes to 1 hour, is spent getting your body into the right position.2
- Sensation. You cannot feel, hear or see the radiation.2
- Afterwards. With external radiotherapy, you are not radioactive and can be around your family as usual.2
- Work. Many men keep working and driving during treatment.11
Preparation. About two to three weeks before treatment starts, you have a planning CT scan. Two or three very small tattoos may be made on the skin to line up your body at every session; some services use other systems instead. At some services, three or four gold markers, the size of a grain of rice, are placed in the prostate with a needle through the perineum, so it shows up on the images at each session.12
Before each session, the team usually asks for a comfortably full bladder and an empty rectum, and tells you how much to drink and when.11,12 It helps to cut down on fruit juice, fizzy drinks, alcohol and caffeine, and on foods that cause gas, such as beans and pulses, leafy greens and spicy food. Some services use a small laxative given into the rectum, a micro-enema, or a medicine to empty the bowel.11,12
In some cases, a gel is placed between the prostate and the rectum before treatment to move the rectum away from the radiation. In a study of 222 men, grade 2 or higher rectal effects at 3 years were 0% with the gel and 5.7% without it.9 The European guideline notes that the gel can have rare but serious complications, such as abscess and fistula.1
When hormone therapy is added
How long depends on the risk group:1
- Intermediate risk: 4 to 6 months alongside radiotherapy. For Gleason 3+4 (ISUP 2) tumors treated with stereotactic radiotherapy, it is not needed.
- High risk: 2 to 3 years.
- Locally advanced disease: at least 2 years. With several risk factors, the guideline adds 2 years of abiraterone.
In an analysis of 12 trials with 10,853 men, adding hormone therapy to radiotherapy lowered the risk of metastasis or death by 17%. Extending treatment after radiotherapy from 4 to 6 months to 18 to 36 months lowered that risk by a further 16%. The authors note that the size of the benefit varies and that the decision should be made with the patient.6
How hormone therapy works and its side effects are covered in hormone therapy for prostate cancer.
What studies show
ProtecT randomly assigned 1,643 men with localized tumors to active monitoring, surgery or radiotherapy and followed them for 15 years:3
| At 15 years | Monitoring | Surgery | Radiotherapy |
|---|---|---|---|
| Death from prostate cancer | 3.1% | 2.2% | 2.9% |
| Metastases | 9.4% | 4.7% | 5% |
The difference in deaths from prostate cancer was not statistically significant.3 In the study, radiotherapy was given in 37 sessions, with an older technique than today's, and 3 to 6 months of hormone therapy.10 The comparison with surgery, effect by effect, is in surgery or radiotherapy.
Radiotherapy after surgery
After a prostatectomy, PSA should be undetectable. When it starts rising again, radiotherapy to the area where the prostate was, called salvage radiotherapy, is one of the options.1
- Sooner is better. The European guideline advises salvage radiotherapy after two consecutive PSA rises, without waiting for a threshold.1 The American guideline advises giving it while PSA is 0.5 ng/mL or lower.7
- Results. More than 60% of men treated before PSA rises above 0.5 ng/mL reach an undetectable PSA, which corresponds to about an 80% chance of being free of progression at 5 years.1
- Hormone therapy alongside. The American guideline advises adding hormone therapy when there are signs of higher risk, such as a PSA of 0.7 ng/mL or more, a high Gleason grade or a PSA that doubles quickly.8
Radiotherapy given soon after surgery, before PSA rises, is called adjuvant radiotherapy. The European guideline notes that the vast majority of men with an undetectable PSA after surgery do not need it, and keeps this option for selected cases of aggressive tumors that have grown beyond the prostate capsule.1 More in PSA after prostatectomy.
Side effects
The side effects most linked to radiotherapy are urinary and bowel effects. With stereotactic radiotherapy in 5 sessions, grade 2 or higher urinary effects at 5 years were 26.9%, versus 18.3% with longer schedules, and bowel effects were the same.5 Hormone therapy, when added, brings the effects of low testosterone.
Tiredness is common, especially towards the end of treatment.13 Radiation only causes hair loss in the area being treated, so the hair on your head does not fall out.14 Some pubic hair may fall out and usually grows back after treatment.13
What may appear years later, and how often, is covered in long-term effects of radiotherapy.
How I approach it
In my practice, when radiotherapy is an option, I compare it with surgery together with the patient, with the numbers and without rushing. I take into account age, urinary symptoms, erections, bowel function, previous surgery and prostate size. I am a surgeon, and I make that clear in the conversation.
I also see men who have had surgery or radiotherapy and whose PSA has started rising again, including for a second opinion.
When to see a urologist
- If you have been diagnosed and want to know whether radiotherapy is an option
- If your PSA has started rising again after surgery
- If your PSA has started rising again after radiotherapy
- If, during or after radiotherapy, you notice blood in your urine, difficulty urinating or pain
Frequently asked questions
Can radiotherapy cure prostate cancer?+
In localized cancer, radiotherapy is given with curative intent. In the ProtecT study, over 15 years, 2.9% of the men treated with radiotherapy died of the disease, versus 2.2% of those who had surgery and 3.1% of those on monitoring, with no statistically significant difference.3
How many radiotherapy sessions are needed for the prostate?+
It depends on the schedule. The traditional one is about 39 sessions over 7.5 weeks. Moderate hypofractionation is 20 sessions over 4 weeks or 28 over 6 weeks. Stereotactic radiotherapy is 5 sessions over 1 to 2 weeks.1,4,5
Does radiotherapy hurt?+
No. You cannot feel, hear or see the radiation. It is delivered for a few minutes, and most of the visit is spent getting you into position.2
How do I prepare for prostate radiotherapy?+
Before treatment starts, you have a planning CT scan. Before each session, the team usually asks for a comfortably full bladder and an empty rectum, and tells you how much to drink. It helps to cut down on fizzy drinks, alcohol, caffeine and foods that cause gas.12
Does prostate radiotherapy make your hair fall out?+
Not the hair on your head, because radiation only causes hair loss in the area being treated.14 Some pubic hair may fall out and usually grows back after treatment.13
Can I work and drive during radiotherapy?+
Many men keep working and driving during treatment.11 Tiredness is common, especially towards the end, and some men need a few days off.12,13
Does external radiotherapy make you radioactive?+
No. After an external radiotherapy session, you are not radioactive.2
References
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2026. Treatment chapter. EAU
- National Cancer Institute (NCI). External Beam Radiation Therapy for Cancer. Reviewed May 2025. NCI
- Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388(17):1547-1558. PubMed
- Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047-1060. PubMed
- van As N, Griffin C, Tree A, et al. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. N Engl J Med. 2024;391(15):1413-1425. PubMed
- Kishan AU, Sun Y, Hartman H, et al. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022;23(2):304-316. PubMed
- Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol. 2024;211(4):509-517. PubMed
- Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024;211(4):518-525. PubMed
- Hamstra DA, Mariados N, Sylvester J, et al. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys. 2017;97(5):976-985. PubMed
- Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016;375(15):1415-1424. PubMed
- Prostate Cancer UK. External beam radiotherapy. Updated March 2026. Prostate Cancer UK
- Prostate Cancer UK. What does external beam radiotherapy involve? Updated March 2026. Prostate Cancer UK
- Prostate Cancer UK. Side effects of external beam radiotherapy. Updated March 2026. Prostate Cancer UK
- National Cancer Institute (NCI). Hair Loss (Alopecia) and Cancer Treatment. Reviewed January 2020. NCI
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation
